flutamide has been researched along with Prostatic Hyperplasia in 41 studies
Flutamide: An antiandrogen with about the same potency as cyproterone in rodent and canine species.
Prostatic Hyperplasia: Increase in constituent cells in the PROSTATE, leading to enlargement of the organ (hypertrophy) and adverse impact on the lower urinary tract function. This can be caused by increased rate of cell proliferation, reduced rate of cell death, or both.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The authors treated 23 benign prostatic hyperplasia (BPH) patients with antiandrogen flutamide." | 9.07 | [The anti-androgen flutamide in the treatment of prostatic hyperplasia]. ( Bach, D; Romics, I, 1992) |
| "To analyze the effects of flutamide in patients with physical and/or mental disorders consulting for urinary symptoms secondary to benign prostatic hyperplasia (BPH)." | 7.70 | [Flutamide, an alternative for patients with benign prostatic hyperplasia (BPH) that cannot be treated with surgery]. ( Granados, EA, 1998) |
| "All flutamide-treated groups had a significant decrease in prostate volume from baseline to the last treatment visit compared to placebo and this reduction was dose related (in comparison to placebo: P < 0." | 6.68 | A dose-response study of the effect of flutamide on benign prostatic hyperplasia: results of a multicenter study. ( Costello, AJ; Das, S; Debruyne, FM; Jimenez-Cruz, JF; Klimberg, I; Lepor, H; Narayan, P; Schellhammer, PF; Shearer, R; Stone, N; Tewari, A; Trachtenberg, J, 1996) |
| "The authors treated 23 benign prostatic hyperplasia (BPH) patients with antiandrogen flutamide." | 5.07 | [The anti-androgen flutamide in the treatment of prostatic hyperplasia]. ( Bach, D; Romics, I, 1992) |
| "One hundred and seventeen elderly male subjects [60 men without symptoms of prostate hyperplasia, 42 men with untreated benign prostatic hyperplasia (BPH), and 15 men with prostate cancer (PCa)] treated with finasteride or flutamide were included." | 3.78 | Prostate cancer in elderly Croatian men: 5-HT genetic polymorphisms and the influence of androgen deprivation therapy on osteopenia--a pilot study. ( Cvijetić, S; Dodig, S; Jurasović, J; Milković-Kraus, S; Mück-Šeler, D; Mustapić, M; Pašalić, D; Pauković, P; Pavlović, M; Pivac, N; Pizent, A, 2012) |
| "To analyze the effects of flutamide in patients with physical and/or mental disorders consulting for urinary symptoms secondary to benign prostatic hyperplasia (BPH)." | 3.70 | [Flutamide, an alternative for patients with benign prostatic hyperplasia (BPH) that cannot be treated with surgery]. ( Granados, EA, 1998) |
| "To investigate the effect of combination endocrine treatment (CET) or luteinising hormone releasing hormone agonist and flutamide on non-neoplastic prostate, prostatic intraepithelial neoplasia, and prostatic adenocarcinoma." | 3.69 | Effects of combination endocrine treatment on normal prostate, prostatic intraepithelial neoplasia, and prostatic adenocarcinoma. ( Fabris, G; Magi-Galluzzi, C; Montironi, R; Muzzonigro, G; Polito, M; Prete, E, 1994) |
| "All flutamide-treated groups had a significant decrease in prostate volume from baseline to the last treatment visit compared to placebo and this reduction was dose related (in comparison to placebo: P < 0." | 2.68 | A dose-response study of the effect of flutamide on benign prostatic hyperplasia: results of a multicenter study. ( Costello, AJ; Das, S; Debruyne, FM; Jimenez-Cruz, JF; Klimberg, I; Lepor, H; Narayan, P; Schellhammer, PF; Shearer, R; Stone, N; Tewari, A; Trachtenberg, J, 1996) |
| "For the endocrine therapy of prostate cancer, chlormadinone acetate, flutamide and bicalutamide are or will be available in Japan." | 2.40 | [Steroidal and nonsteroidal antiandrogens: chemical structures, mechanisms of action and clinical applications]. ( Akakura, K; Furuya, Y; Ito, H, 1998) |
| "Antiandrogen therapy for benign prostatic hyperplasia (BPH) and prostatic carcinoma has been introduced in clinical practice." | 2.39 | [Application of antiandrogens on prostatic diseases]. ( Hasegawa, F; Isurugi, K; Takahashi, S, 1994) |
| " Pharmacokinetic study with compound 10 at an oral dose of 10." | 1.37 | Arylpiperazines for management of benign prostatic hyperplasia: design, synthesis, quantitative structure-activity relationships, and pharmacokinetic studies. ( Dalela, D; Gupta, G; Jain, A; Kumar, L; Kumar, R; Lal, J; Lal, N; Maikhuri, JP; Pandey, SK; Prabhakar, YS; Sarswat, A; Sharma, S; Sharma, VL; Verma, V, 2011) |
| "Thirty patients with prostate cancer arising and localizing in the peripheral zone were enrolled in this study." | 1.32 | Influence of androgen deprivation therapy on volume of anatomic zones of prostate in patients with prostate cancer using magnetic resonance imaging. ( Nishiyama, T; Takahashi, K; Tomita, Y, 2004) |
| "Their density in prostatic cancer increases following hormonal therapy and varies in relation to the tumoral degree or histological evaluation, suggesting a role of neuroendocrine cells in human prostatic cancer." | 1.30 | Neuroendocrine cells in benign prostatic hyperplasia and prostatic carcinoma: effect of hormonal treatment. ( del Valle, M; Escaf, S; Guate, JL; Menendez, CL; Vega, JA, 1997) |
| " 2) The weight and volume of the mouse prostate diminished in Flu-treated groups, but the dose-response relationship was seen only in volume." | 1.30 | Flutamide suppressed prostate hypertrophy in rats and mice. ( Chen, BL; Li, D; Li, PF; Zhang, YY, 1999) |
| "Flutamide appears to cause hepatotoxic effects in certain patients." | 1.29 | Fatal and nonfatal hepatotoxicity associated with flutamide. ( Freiman, JP; Horton, ML; Tourtelot, JB; Wysowski, DK, 1993) |
| " To determine the specificity of the HF effect, we measured the DHT/HF index in a single prostate at different concentrations of HF in the presence of fixed concentrations of DHT (2 x 10(-8) M) and noted a dose-response relationship." | 1.28 | Measurement of androgen sensitivity in the human prostate in in vitro three-dimensional histoculture. ( Connors, K; Geller, J; Hoffman, RM; Sionit, LR, 1992) |
| " The daily dosage of terazosin was titrated to 5 mg over a 2-week interval." | 1.28 | The relative efficacy of terazosin versus terazosin and flutamide for the treatment of symptomatic BPH. ( Lepor, H; Machi, G, 1992) |
| "Benign prostatic hypertrophy is a highly prevalent disease, with a significant morbidity." | 1.28 | [Non-surgical treatment of benign prostatic hypertrophy. Current status of the problem]. ( Van Cangh, PJ, 1992) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 11 (26.83) | 18.7374 |
| 1990's | 23 (56.10) | 18.2507 |
| 2000's | 4 (9.76) | 29.6817 |
| 2010's | 3 (7.32) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Sarswat, A | 1 |
| Kumar, R | 1 |
| Kumar, L | 1 |
| Lal, N | 1 |
| Sharma, S | 1 |
| Prabhakar, YS | 1 |
| Pandey, SK | 1 |
| Lal, J | 1 |
| Verma, V | 1 |
| Jain, A | 1 |
| Maikhuri, JP | 1 |
| Dalela, D | 1 |
| Gupta, G | 1 |
| Sharma, VL | 1 |
| Oliver, VL | 1 |
| Anderson, C | 1 |
| Ventura, S | 1 |
| Haynes, JM | 1 |
| Pašalić, D | 1 |
| Pauković, P | 1 |
| Cvijetić, S | 1 |
| Pizent, A | 1 |
| Jurasović, J | 1 |
| Milković-Kraus, S | 1 |
| Dodig, S | 1 |
| Mück-Šeler, D | 1 |
| Mustapić, M | 1 |
| Pivac, N | 1 |
| Pavlović, M | 1 |
| Nishiyama, T | 1 |
| Tomita, Y | 1 |
| Takahashi, K | 1 |
| Benaim, EA | 1 |
| Karam, JA | 1 |
| Soboorian, MH | 1 |
| Roehrborn, CG | 1 |
| McConnell, JD | 2 |
| Lin, V | 1 |
| Gao, W | 1 |
| Kearbey, JD | 1 |
| Nair, VA | 1 |
| Chung, K | 1 |
| Parlow, AF | 1 |
| Miller, DD | 1 |
| Dalton, JT | 1 |
| Oliveira, SM | 1 |
| Leite Vilamaior, PS | 1 |
| Corradi, LS | 1 |
| Góes, RM | 1 |
| Taboga, SR | 1 |
| Geller, J | 3 |
| Albert, J | 1 |
| Nachtsheim, DA | 1 |
| Loza, D | 1 |
| Geller, S | 1 |
| Takahashi, S | 1 |
| Hasegawa, F | 1 |
| Isurugi, K | 1 |
| Caine, M | 2 |
| Sionit, LR | 2 |
| Baird, A | 1 |
| Kohls, M | 1 |
| Connors, KM | 1 |
| Hoffman, RM | 2 |
| Montironi, R | 1 |
| Magi-Galluzzi, C | 1 |
| Muzzonigro, G | 1 |
| Prete, E | 1 |
| Polito, M | 1 |
| Fabris, G | 1 |
| el Etreby, MF | 1 |
| Habenicht, UF | 1 |
| Horninger, W | 1 |
| Bartsch, G | 1 |
| Brenner, PC | 1 |
| Rettig, WJ | 1 |
| Sanz-Moncasi, MP | 1 |
| Reuter, V | 1 |
| Aprikian, A | 1 |
| Old, LJ | 1 |
| Fair, WR | 1 |
| Garin-Chesa, P | 1 |
| Tutrone, RF | 1 |
| Ball, RA | 1 |
| Ornitz, DM | 1 |
| Leder, P | 1 |
| Richie, JP | 1 |
| Wysowski, DK | 1 |
| Freiman, JP | 1 |
| Tourtelot, JB | 1 |
| Horton, ML | 1 |
| Marshall, S | 1 |
| Narayan, P | 2 |
| Strohmaier, WL | 1 |
| Flüchter, SH | 1 |
| Wilbert, DM | 1 |
| Bichler, KH | 1 |
| Benassayag, E | 1 |
| Trachtenberg, J | 1 |
| Lepor, H | 2 |
| Debruyne, FM | 1 |
| Tewari, A | 1 |
| Stone, N | 1 |
| Das, S | 1 |
| Jimenez-Cruz, JF | 1 |
| Shearer, R | 1 |
| Klimberg, I | 1 |
| Schellhammer, PF | 1 |
| Costello, AJ | 1 |
| Guate, JL | 1 |
| Escaf, S | 1 |
| Menendez, CL | 1 |
| del Valle, M | 1 |
| Vega, JA | 1 |
| Akakura, K | 1 |
| Furuya, Y | 1 |
| Ito, H | 1 |
| Granados, EA | 1 |
| Zhang, YY | 1 |
| Li, PF | 1 |
| Chen, BL | 1 |
| Li, D | 1 |
| Bonard, M | 1 |
| de Almeida, S | 1 |
| von Niederhäusern, W | 1 |
| Prout, GR | 1 |
| Kliman, B | 1 |
| Daly, JJ | 1 |
| Maclaughlin, RA | 1 |
| Griffin, PP | 1 |
| Neri, RO | 1 |
| Perlberg, S | 1 |
| Gordon, R | 1 |
| Syrkin, AB | 1 |
| Smirnova, IO | 1 |
| Lazarev, NI | 1 |
| Lakey, WH | 1 |
| Bruchovsky, N | 1 |
| Callaway, T | 1 |
| Comeau, T | 1 |
| Lieskovsky, G | 1 |
| Rennie, P | 1 |
| Shnitka, T | 1 |
| Wilkin, P | 1 |
| Romics, I | 1 |
| Bach, D | 1 |
| Connors, K | 1 |
| Levine, AC | 1 |
| Ren, M | 1 |
| Huber, GK | 1 |
| Kirschenbaum, A | 1 |
| Machi, G | 1 |
| Van Cangh, PJ | 1 |
| Petrangeli, E | 1 |
| Sciarra, F | 1 |
| Di Silverio, F | 1 |
| Toscano, V | 1 |
| Lubrano, C | 1 |
| Conti, C | 1 |
| Concolino, G | 1 |
| Namer, M | 1 |
| Neri, R | 1 |
| Stone, NN | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Medical Therapy of Prostatic Symptoms[NCT00021814] | Phase 3 | 3,407 participants (Actual) | Interventional | 1995-12-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
9 reviews available for flutamide and Prostatic Hyperplasia
| Article | Year |
|---|---|
[Application of antiandrogens on prostatic diseases].
Topics: Androgen Antagonists; Chlormadinone Acetate; Clinical Trials as Topic; Flutamide; Humans; Male; Pros | 1994 |
[Terazosine in the treatment of benign prostatic hypertrophy].
Topics: Administration, Oral; Adrenergic alpha-Antagonists; Drug Therapy, Combination; Flutamide; Humans; Ma | 1993 |
The function and the role of aromatase inhibitors in the treatment of BPH.
Topics: Androgens; Androstenedione; Animals; Aromatase Inhibitors; Clinical Trials as Topic; Disease Models, | 1994 |
[Hormonal therapy of benign prostatic hyperplasia].
Topics: 5-alpha Reductase Inhibitors; Adult; Aged; Androgen Antagonists; Clinical Trials as Topic; Cyprotero | 1995 |
[Steroidal and nonsteroidal antiandrogens: chemical structures, mechanisms of action and clinical applications].
Topics: Androgen Antagonists; Anilides; Chlormadinone Acetate; Flutamide; Humans; Male; Neoplasms, Hormone-D | 1998 |
Antiandrogens.
Topics: Acne Vulgaris; Androgen Antagonists; Animals; Biological Assay; Comb and Wattles; Cyproterone; Femal | 1976 |
Androgen ablation and blockade in the treatment of benign prostatic hyperplasia.
Topics: 5-alpha Reductase Inhibitors; Androgen Antagonists; Androstenes; Azasteroids; Finasteride; Flutamide | 1990 |
Clinical applications of antiandrogens.
Topics: Androgen Antagonists; Breast Neoplasms; Cyproterone; Cyproterone Acetate; Female; Flutamide; Humans; | 1988 |
Pharmacology and pharmacokinetics of flutamide.
Topics: Anilides; Animals; Flutamide; Male; Prostate; Prostatic Hyperplasia; Seminal Vesicles | 1989 |
8 trials available for flutamide and Prostatic Hyperplasia
| Article | Year |
|---|---|
The effect of combined androgen ablation on the expression of alpha1A-adrenergic receptor in the human prostate.
Topics: Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Flutamide; Humans; Leuprolide; Male; Mi | 2004 |
[Indications of antiandrogens in benign hyperplasia of the prostate].
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Cyproterone Acetate; Flutamide; Humans; Imidazoles; I | 1995 |
A dose-response study of the effect of flutamide on benign prostatic hyperplasia: results of a multicenter study.
Topics: Aged; Androgen Antagonists; Dose-Response Relationship, Drug; Double-Blind Method; Flutamide; Humans | 1996 |
Placebo-controlled double-blind study in human benign obstructive prostatic hypertrophy with flutamide.
Topics: Anilides; Clinical Trials as Topic; Flutamide; Humans; Male; Middle Aged; Organ Size; Placebos; Pros | 1976 |
The treatment of benign prostatic hypertrophy with flutamide (SCH: 13521): a placebo-controlled study.
Topics: Anilides; Biopsy, Needle; Clinical Trials as Topic; Flutamide; Gynecomastia; Humans; Male; Placebos; | 1975 |
[The anti-androgen flutamide in the treatment of prostatic hyperplasia].
Topics: Androgen Antagonists; Dose-Response Relationship, Drug; Flutamide; Humans; Male; Prostatic Hyperplas | 1992 |
Effects of two different medical treatments on dihydrotestosterone content and androgen receptors in human benign prostatic hyperplasia.
Topics: Androgen Antagonists; Anilides; Cell Nucleus; Cyproterone; Cyproterone Acetate; Cytosol; Dihydrotest | 1988 |
Flutamide in treatment of benign prostatic hypertrophy.
Topics: Anilides; Double-Blind Method; Flutamide; Humans; Male; Multicenter Studies as Topic; Prostatic Hype | 1989 |
24 other studies available for flutamide and Prostatic Hyperplasia
| Article | Year |
|---|---|
Arylpiperazines for management of benign prostatic hyperplasia: design, synthesis, quantitative structure-activity relationships, and pharmacokinetic studies.
Topics: Androgen Antagonists; Animals; Antineoplastic Agents; Blood-Brain Barrier; Drug Design; Drug Screeni | 2011 |
Androgens regulate adenylate cyclase activity and intracellular calcium in stromal cells derived from human prostate.
Topics: Adenylyl Cyclase Inhibitors; Adenylyl Cyclases; Aged; Androgen Antagonists; Androgens; Calcium; Cycl | 2010 |
Prostate cancer in elderly Croatian men: 5-HT genetic polymorphisms and the influence of androgen deprivation therapy on osteopenia--a pilot study.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Bone Density; Bone Diseases, Metabolic; Finasteride; | 2012 |
Influence of androgen deprivation therapy on volume of anatomic zones of prostate in patients with prostate cancer using magnetic resonance imaging.
Topics: Aged; Androgen Antagonists; Flutamide; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Orchie | 2004 |
Comparison of the pharmacological effects of a novel selective androgen receptor modulator, the 5alpha-reductase inhibitor finasteride, and the antiandrogen hydroxyflutamide in intact rats: new approach for benign prostate hyperplasia.
Topics: 3-Oxo-5-alpha-Steroid 4-Dehydrogenase; 5-alpha Reductase Inhibitors; Androgen Antagonists; Androgens | 2004 |
Cellular and extracellular behavior in the gerbil (Meriones unguiculatus) ventral prostate following different types of castration and the consequences of testosterone replacement.
Topics: Acid Phosphatase; Androgen Antagonists; Animals; Cyproterone; Disease Models, Animal; Endoplasmic Re | 2007 |
The effects of flutamide on total DHT and nuclear DHT levels in the human prostate.
Topics: Acid Phosphatase; Administration, Oral; Anilides; Cell Nucleus; Dihydrotestosterone; Flutamide; Huma | 1981 |
In vivo and in vitro effects of androgen on fibroblast growth factor-2 concentrations in the human prostate.
Topics: Androgen Antagonists; Cell Division; Culture Techniques; Dihydrotestosterone; Fibroblast Growth Fact | 1994 |
Effects of combination endocrine treatment on normal prostate, prostatic intraepithelial neoplasia, and prostatic adenocarcinoma.
Topics: Adenocarcinoma; Aged; Carcinoma in Situ; Drug Therapy, Combination; Flutamide; Gonadotropin-Releasin | 1994 |
TAG-72 expression in primary, metastatic and hormonally treated prostate cancer as defined by monoclonal antibody CC49.
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antigens, Neoplasm; Bone Neoplasms; Flutamide; Glycoproteins | 1995 |
Benign prostatic hyperplasia in a transgenic mouse: a new hormonally sensitive investigatory model.
Topics: 5-alpha Reductase Inhibitors; Androstenes; Animals; Azasteroids; Dihydrotestosterone; Disease Models | 1993 |
Fatal and nonfatal hepatotoxicity associated with flutamide.
Topics: Adverse Drug Reaction Reporting Systems; Aged; Aged, 80 and over; Antineoplastic Combined Chemothera | 1993 |
Treatment of prostatic bleeding: suppression of angiogenesis by androgen deprivation.
Topics: Aged; Aged, 80 and over; Diethylstilbestrol; Estrogens, Conjugated (USP); Flutamide; Hematuria; Huma | 1993 |
Influence of transrectal hyperthermia on prostate-specific antigen in prostatic cancer and benign prostatic hyperplasia.
Topics: Aged; Combined Modality Therapy; Epirubicin; Flutamide; Humans; Hyperthermia, Induced; Male; Prostat | 1993 |
Neuroendocrine cells in benign prostatic hyperplasia and prostatic carcinoma: effect of hormonal treatment.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; | 1997 |
[Flutamide, an alternative for patients with benign prostatic hyperplasia (BPH) that cannot be treated with surgery].
Topics: Androgen Antagonists; Flutamide; Humans; Male; Middle Aged; Prostatic Hyperplasia | 1998 |
Flutamide suppressed prostate hypertrophy in rats and mice.
Topics: Androgen Antagonists; Animals; Dose-Response Relationship, Drug; Estradiol; Flutamide; Male; Mice; O | 1999 |
In vitro uptake of 3H testosterone and its conversion to dihydrotestosterone by prostatic carcinoma and other tissues.
Topics: Aged; Culture Techniques; Diethylstilbestrol; Dihydrotestosterone; Flutamide; Humans; Lymphatic Meta | 1976 |
The treatment of hypertrophy of the prostate of rats with 4-nitro-3-trifluoromethylisobutyranilide (Sch 13521).
Topics: Anilides; Animals; Behavior, Animal; Castration; Flutamide; Male; Organ Size; Prostate; Prostatic Hy | 1977 |
Androgen receptors in benign and malignant prostatic tissue.
Topics: 3-Oxo-5-alpha-Steroid 4-Dehydrogenase; Androgen Antagonists; Animals; Cyproterone; Dihydrotestostero | 1979 |
Measurement of androgen sensitivity in the human prostate in in vitro three-dimensional histoculture.
Topics: Androgen Antagonists; Androgen Receptor Antagonists; Dihydrotestosterone; Flutamide; Histological Te | 1992 |
The effect of androgen, estrogen, and growth factors on the proliferation of cultured fibroblasts derived from human fetal and adult prostates.
Topics: Cell Division; Cells, Cultured; Dihydrotestosterone; Epidermal Growth Factor; Estradiol; Female; Fet | 1992 |
The relative efficacy of terazosin versus terazosin and flutamide for the treatment of symptomatic BPH.
Topics: Adrenergic alpha-Antagonists; Aged; Drug Therapy, Combination; Flutamide; Humans; Male; Middle Aged; | 1992 |
[Non-surgical treatment of benign prostatic hypertrophy. Current status of the problem].
Topics: Androgen Antagonists; Aromatase Inhibitors; Cholestenone 5 alpha-Reductase; Cyproterone Acetate; Enz | 1992 |